Drug Trial Radar · NCT07612280
Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Essential Thrombocythemia (ET) and Polycythemia Vera (PV) With Thrombocytosis
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Oct 21, 2024
Primary completion
Jan 30, 2031
Study completion Jan 30, 2031
Sponsor
- Lead sponsor
- Jubilant Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- May 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2 study is evaluating the safety and preliminary effectiveness of JBI-802, an oral investigational medicine, in adults with essential thrombocythemia (ET) or polycythemia vera (PV) with thrombocytosis (high platelet counts). The study has two parts. Part 1 evaluates different doses to select the recommended Phase 2 dose. The initial dose-escalation portion is complete, and additional participants may receive selected doses to further assess safety and activity. Part 2 will evaluate the selected dose in a larger group of participants with ET or PV. JBI-802 is taken by mouth once daily in 28-day treatment cycles. Participants may continue treatment while they are benefiting, tolerating treatment, and meeting study requirements. Study assessments include medical examinations, laboratory tests, electrocardiograms, symptom assessments, bone marrow evaluations, and imaging when needed.
Conditions
- Essential Thrombocythemia (ET)
- Polycythemia Vera
Interventions
JBI-802Drug
CoREST inhibitor dual targeting LSD1 and HDAC6
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation - Incidence of Dose-Limiting Toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Dose Expansion - Platelet countTime frame: Up to 2 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Hollywood Private Hospital
Nedlands, Australia · Recruiting
St. Vincent's Hospital Sydney Limited
Sydney, New South Wales, Australia · Recruiting
Macquarie University
Sydney, New South Wales, Australia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
St Vincent's Hospital (Melbourne)
Melbourne, Victoria, Australia · Recruiting
Monash Medical Centre
Melbourne, Victoria, Australia · Recruiting
The Perth Blood Institute Limited
Perth, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.